DE69815090T2 - Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen - Google Patents

Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen Download PDF

Info

Publication number
DE69815090T2
DE69815090T2 DE69815090T DE69815090T DE69815090T2 DE 69815090 T2 DE69815090 T2 DE 69815090T2 DE 69815090 T DE69815090 T DE 69815090T DE 69815090 T DE69815090 T DE 69815090T DE 69815090 T2 DE69815090 T2 DE 69815090T2
Authority
DE
Germany
Prior art keywords
group
benzyl
methylpiperidine
dimethoxy
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69815090T
Other languages
German (de)
English (en)
Other versions
DE69815090D1 (de
Inventor
L. Sharon ROGERS
T. Lawrence FRIEDHOFF
J. Paul TISEO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai Co Ltd
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Application granted granted Critical
Publication of DE69815090D1 publication Critical patent/DE69815090D1/de
Publication of DE69815090T2 publication Critical patent/DE69815090T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69815090T 1997-03-03 1998-03-03 Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen Expired - Lifetime DE69815090T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3983297P 1997-03-03 1997-03-03
US39832P 1997-03-03
PCT/IB1998/000508 WO1998039000A1 (en) 1997-03-03 1998-03-03 Use of cholinesterase inhibitors to treat disorders of attention

Publications (2)

Publication Number Publication Date
DE69815090D1 DE69815090D1 (de) 2003-07-03
DE69815090T2 true DE69815090T2 (de) 2004-02-19

Family

ID=21907565

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69815090T Expired - Lifetime DE69815090T2 (de) 1997-03-03 1998-03-03 Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen

Country Status (12)

Country Link
US (2) US6455544B1 (https=)
EP (1) EP0971713B1 (https=)
JP (1) JP4095676B2 (https=)
AT (1) ATE241358T1 (https=)
AU (1) AU743609B2 (https=)
CA (1) CA2282654C (https=)
DE (1) DE69815090T2 (https=)
DK (1) DK0971713T3 (https=)
ES (1) ES2200313T3 (https=)
NZ (1) NZ337515A (https=)
PT (1) PT971713E (https=)
WO (1) WO1998039000A1 (https=)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0971713B1 (en) * 1997-03-03 2003-05-28 Eisai Co., Ltd. Use of cholinesterase inhibitors to treat disorders of attention
GB9716879D0 (en) * 1997-08-08 1997-10-15 Shire Int Licensing Bv Treatment of attention deficit disorders
US6429207B1 (en) 1997-11-21 2002-08-06 Nps Pharmaceuticals, Inc. Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
US20060183776A9 (en) * 2000-03-03 2006-08-17 Eisai Co., Ltd. Liquid dosage formulations of donepezil
US20030153598A1 (en) * 2000-07-25 2003-08-14 Raymond Pratt Methods for treating Parkinson's disease with cholinesterase inhibitors
EP1311272B1 (en) 2000-03-03 2006-11-22 Eisai Co., Ltd. Novel methods using cholinesterase inhibitors
EP1764101A1 (en) * 2000-03-03 2007-03-21 Eisai R&D Management Co., Ltd. Use of a cholinesterase inhibitor for the treatment of dementia and cognitive impairments
JP2006516948A (ja) * 2000-11-14 2006-07-13 ニュー リバー ファーマシューティカルズ インコーポレイテッド 硫酸アバカビルを含有する新規な薬剤化合物および同化合物の製造ならびに使用方法
WO2004034963A2 (en) * 2002-05-17 2004-04-29 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
US20070053976A1 (en) * 2002-05-17 2007-03-08 Eisai R & D Management Co., Ltd. Novel combination of drugs as antidepressant
US7589199B2 (en) 2002-06-12 2009-09-15 Chemocentryx, Inc. Substituted piperazines
DK1531822T3 (da) 2002-06-12 2009-12-07 Chemocentryx Inc 1-aryl-4-substituerede piperazin derivater til anvendelse som CCR1 antagonister til behandlingen af inflammation og immunforstyrrelser
US7842693B2 (en) 2002-06-12 2010-11-30 Chemocentryx, Inc. Substituted piperazines
US20050256130A1 (en) * 2002-06-12 2005-11-17 Chemocentryx, Inc. Substituted piperazines
WO2005065645A2 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Donepezil formulations
US7435830B2 (en) * 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
US7435831B2 (en) 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
JP4696062B2 (ja) * 2004-04-28 2011-06-08 エーザイ・アール・アンド・ディー・マネジメント株式会社 １−ベンジル−４−［（５，６−ジメトキシ−１−インダノン）−２−イル］メチルピペリジンおよびその塩酸塩の製造法
WO2006036936A2 (en) * 2004-09-27 2006-04-06 Bridge Pharma, Inc. The s-isomer of 2-{2-[n-(2-indanyl)-n-phenylamino]ethyl}piperidine and other dermal anesthetic agents
US20060079558A1 (en) * 2004-09-27 2006-04-13 Bridge Pharma. Inc. R-isomer of 2-{2[N-(2-indanyl)-N-phenylamino]ethyl}piperidine and other dermal anesthetics
CA2589102C (en) 2004-11-02 2013-08-13 Northwestern University Pyridazine compounds and methods for using the compounds to treat inflammatory diseases
WO2006081332A1 (en) * 2005-01-25 2006-08-03 Epix Delaware, Inc. Substituted arylamine compounds and their use as 5-ht6 modulators
US20060270709A1 (en) * 2005-04-04 2006-11-30 Eisai Co. Ltd. Dihydropyridine compounds and compositions for headaches
CA2624805A1 (en) * 2005-10-14 2007-04-19 Eisai R&D Management Co., Ltd. Process for producing 1-benzyl-4-[(5,6-dimethoxy-1­indanon)-2-yl]methylpiperidine or hydrochloride thereof
CN101410374A (zh) * 2005-11-14 2009-04-15 麦迪凯姆股份公司 用于制备盐酸多奈哌齐的中间体和其新多晶型物的改良的合成和制备
CA2650711A1 (en) 2006-04-28 2007-11-08 Northwestern University Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
US7592458B2 (en) * 2006-07-21 2009-09-22 Wright George E Dermal anesthetic compounds and pharmaceutical compositions for inducing local anesthesia and mitigating neuropathic pain
US20100048628A1 (en) * 2006-12-01 2010-02-25 Sumiyo Nishi Method for suppressing discoloration over time of adhesive preparation containing donepezil
JP5237112B2 (ja) * 2006-12-01 2013-07-17 日東電工株式会社 経皮吸収製剤
US20100099714A1 (en) * 2007-03-05 2010-04-22 Eisai R&D Management Co., Ltd. AMPA and NMDA Receptor Antagonists for Neurodegenerative Diseases
EP2148673A1 (en) * 2007-04-26 2010-02-03 Eisai R&D Management Co., Ltd. Cinnamide compounds for dementia
KR100914691B1 (ko) * 2007-08-10 2009-08-28 주식회사유한양행 도네페질 또는 그의 제조용 중간체의 제조방법
KR20110020788A (ko) * 2008-05-30 2011-03-03 에자이 알앤드디 매니지먼트 가부시키가이샤 경피 흡수 제제
WO2009145177A1 (ja) * 2008-05-30 2009-12-03 日東電工株式会社 ドネペジル含有貼付製剤およびその包装体
EA202092673A3 (ru) 2010-02-09 2021-05-31 Дзе Джонс Хопкинс Юниверсити Способы и композиции для улучшения когнитивной функции
WO2012071369A2 (en) 2010-11-24 2012-05-31 The Trustees Of Columbia University In The City Of New York A non-retinoid rbp4 antagonist for treatment of age-related macular degeneration and stargardt disease
WO2013166037A1 (en) 2012-05-01 2013-11-07 The Trustees Of Columbia University In The City Of New York Non-retinoid antagonists for treatment of eye disorders
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
US9944644B2 (en) 2013-03-14 2018-04-17 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles their preparation and use
US9637450B2 (en) 2013-03-14 2017-05-02 The Trustees Of Columbia University In The City Of New York Octahydrocyclopentapyrroles, their preparation and use
US9938291B2 (en) 2013-03-14 2018-04-10 The Trustess Of Columbia University In The City Of New York N-alkyl-2-phenoxyethanamines, their preparation and use
EP2968304B1 (en) 2013-03-14 2018-10-10 The Trustees of Columbia University in the City of New York 4-phenylpiperidines, their preparation and use
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
AU2014228512A1 (en) 2013-03-15 2015-10-01 Agenebio, Inc. Methods and compositions for improving cognitive function
EP4036094B1 (en) 2014-04-30 2025-12-24 The Trustees of Columbia University in the City of New York Substituted 4-phenylpiperidines, their preparation and use
KR101732776B1 (ko) * 2014-10-08 2017-05-04 영남대학교 산학협력단 신규한 인데노 피리디니움 유도체 화합물 및 이의 제조방법
CA2986598C (en) 2015-05-22 2023-09-26 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI95572C (fi) * 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
US5064858A (en) * 1988-08-17 1991-11-12 Spectrum Pharmaceutical Corporation Protected complex of procaine for the treatment of symptoms from narcotics addiction, tinnitus and Alzheimer's disease
WO1997003671A1 (en) * 1995-07-14 1997-02-06 Medeva Europe Limited Composition comprising d-threo-methylphenidate and another drug
SI9720038B (sl) * 1996-06-07 2010-06-30 Eisai Co Ltd Polimorfi donepezil hidroklorida in postopek izdelave
EP0971713B1 (en) * 1997-03-03 2003-05-28 Eisai Co., Ltd. Use of cholinesterase inhibitors to treat disorders of attention

Also Published As

Publication number Publication date
US7105540B2 (en) 2006-09-12
JP2001515480A (ja) 2001-09-18
NZ337515A (en) 2002-07-26
US6455544B1 (en) 2002-09-24
PT971713E (pt) 2003-09-30
EP0971713A1 (en) 2000-01-19
DK0971713T3 (da) 2003-09-22
WO1998039000A1 (en) 1998-09-11
JP4095676B2 (ja) 2008-06-04
EP0971713B1 (en) 2003-05-28
CA2282654A1 (en) 1998-09-11
ATE241358T1 (de) 2003-06-15
DE69815090D1 (de) 2003-07-03
ES2200313T3 (es) 2004-03-01
CA2282654C (en) 2009-02-03
AU7321598A (en) 1998-09-22
AU743609B2 (en) 2002-01-31
US20030055040A1 (en) 2003-03-20

Similar Documents

Publication Publication Date Title
DE69815090T2 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
DE3855028T2 (de) 1,4-Substituierte Piperidine als Acetylcholinesterase Inhibitoren und ihre Verwendung zur Behandlung von Alzheimer's Erkrankung
DE60124730T2 (de) Neue methoden unter verwendung von cholinesteraseinhibitoren
DE69838179T2 (de) Chronische bolusgabe von d-threo methylphenidat
DE69535234T2 (de) Mittel zur behandlung der allergischen rhinitis und anderer erkrankungen enthaltend descarboethoxyloratadin
DE19542281C2 (de) Verwendung von Epinastin für die Behandlung der Migräne
DE69903750T2 (de) Verwendung von langkettigen n-alkyl derivaten von deoxynojirimycin zur herstellung eines medikaments zur behandlung von mit glykolipiden akkumulation zusammenhängenden krankheiten
DE69507419T2 (de) Verwendung von einem Tetrahydropyridin- oder azabicyclischen Oxadiazol- oder -Thiadiazol-Verbindung zur Behandlung von Angstzuständen
WO2002020521A1 (de) Verwendung von indolderivaten zur behandlung von erkrankungen des zentralen nervensystems
DE69320952T2 (de) Verwendung von terfenadin-derivaten als antihistaminika in leberkranken patienten
DE69825605T2 (de) Behandlung der schizophrenie und der psychose
DE69908421T2 (de) Pharmazeutische zusammensetzung enthaltend eine kombination der dextro- und laevo-isomeren von sotalol
DE69326459T2 (de) Wirkstoffe zur behandlung von suchterkrankungen
JPH0354922B2 (https=)
DE2362958A1 (de) N-substituiertes pyridon und verfahren zur herstellung von pyridon-verbinnungen
EP0003602B1 (de) Pyrrolidin-Derivate zur Anwendung als therapeutische Wirkstoffe und diese enthaltende Arzneimittel
DE68907392T2 (de) Dysmnesie modifizierende Arzneimittel.
DE69815518T2 (de) S-2'-(2-(1-methyl-2-piperidyl) ethyl) cinnamanilide als 5-ht2 rezeptor antagonist
DD202539A5 (de) Verfahren zur herstellung von 1-(3-hydroxy-4-methoxybenzoyl)-3-hydroxy-2-pyrolidinon
DE60216776T2 (de) Neue piperidin-2,6-dion bisulfatsalze und deren verwendung für die behandlung stressbezogener gemütserkrankungen
DE69814089T2 (de) Verwendung von einem draflazin analog zur schmerzbehandlung
US5434177A (en) Imidazoles for the treatment of age-related cognitive disorders and alzheimer
DE19906975A1 (de) Vorrichtung und Verfahren zur Behandlung von Alzheimer'scher Demenz
DE3889043T2 (de) N-(substituiertes Alkyliden)-1,2,3,4-tetrahydro-9-acridinamine, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikamente.
DE69032046T2 (de) Tetrahydroisochinolinylcarbamate von 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo [2,3-b] indol

Legal Events

Date Code Title Description
8364 No opposition during term of opposition